Feds’ wearable push raises alarms
Federal investment in wearable health trackers is expanding—but privacy advocates warn physiological data could leak to brokers, law enforcement, or advertisers if not protected, creating a new 'grey zone' outside HIPAA. Startups that collect heart rate, sleep, or stress metrics now face intensified scrutiny over data-sharing and safeguards. (reason.com)
ARPA‑H formally launched the Delphi biosensor program on March 10, 2026 to accelerate low‑cost, next‑generation wearable and ingestible biosensors. (arpa-h.gov) Agency materials and reporting say Delphi targets modular “chiplet” sensors and aims to push devices that can report biochemical signals beyond heart rate or SpO2, including cytokines and hormones. (fiercebiotech.com) The program is structured in multi‑phase awards with an expected 4.5‑year span, a two‑year prototype window before component integration, and early submission deadlines for proposers in April 2026. (biotechgrid.com) Federal support for digital biomarkers and wearables already extends into NIH funding streams via NOFOs such as PAR‑24‑250 (standardizing wearable data/metadata) and PAR‑25‑170 (digital‑health‑derived biomarkers for remote monitoring). (grants.nih.gov) ARPA‑H sits on a multibillion federal appropriation—Congress allocated $1.5 billion to ARPA‑H in the FY2024 omnibus—giving the agency capacity to fund programs like Delphi at scale. (arpa-h.gov) Federal and advocacy trackers note a regulatory gap: HHS guidance and industry analyses confirm HIPAA generally does not cover consumer wearables unless data flows to a covered entity, leaving many device‑collected biometrics outside HIPAA protections. (hhs.gov) Privacy groups and reporting warn that commercial data‑broker pipelines and law‑enforcement purchases of third‑party location and app data create practical routes for physiological datasets to be accessed outside clinical safeguards. (brennancenter.org) Policymakers and professional groups have started proposing new guardrails—legislative attention to wearable consent and calls for HIPAA‑style or “sensitive health data” rules have risen amid ARPA‑H’s push and broader agency activity. (politico.com)
